- Home
- GLV vs TLPH Comparison
GLV vs TLPH Comparison
Compare GLV & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.00
Company Overview
Basic Information| Metric | GLV | TLPH |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 64.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GLV | TLPH |
|---|---|---|
| Price | $6.31 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 54.2K | ★ 475.9K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 12.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.70 | $0.38 |
| 52 Week High | $6.06 | $1.57 |
Technical Indicators
Market Signals| Indicator | GLV | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 71.72 | 38.49 |
| Support Level | $6.19 | $0.97 |
| Resistance Level | $6.27 | $1.07 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 97.37 | 9.37 |
Price Performance
Historical Comparison GLV
TLPH
About GLV Clough Global Dividend and Income Fund of beneficial interest
Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.